Compare LSBK & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LSBK | ARMP |
|---|---|---|
| Founded | 1891 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.5M | 199.7M |
| IPO Year | 2025 | 1996 |
| Metric | LSBK | ARMP |
|---|---|---|
| Price | $18.26 | $3.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 23.4K | ★ 251.8K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | ★ 49.23 | N/A |
| EPS | ★ 0.56 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.62 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.50 | $2.94 |
| 52 Week High | $19.09 | $14.98 |
| Indicator | LSBK | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 61.10 | N/A |
| Support Level | $16.84 | N/A |
| Resistance Level | $19.09 | N/A |
| Average True Range (ATR) | 0.59 | 0.00 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 55.65 | 0.00 |
Lake Shore Bancorp Inc operates as a savings and loan holding company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit, and, to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.